Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Sponsor: National Cancer Institute (NCI)
This PHASE2 trial investigates Advanced Malignant Solid Neoplasm and Glioblastoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 74 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
74 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 69 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Sep 2018 — Jan 2019 [monthly]
Suspended PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Suspended PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — May 2018 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States , Baltimore, United States , Boston, United States , Chapel Hill, United States , City of Saint Peters, United States , Columbus, United States , Coral Gables, United States , Costa Mesa, United States , Creve Coeur, United States , Deerfield Beach, United States and 28 more locations